Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Name: Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?
Uploaded: 2019-03-11T00:00:00+00:00

Created by

Presenter

Michael Blaha, MD, MPH

Director of Clinical ResearchCiccarone Center for the Prevention of Heart DiseaseAssociate Professor of MedicineJohns Hopkins School of MedicineBaltimore, MD